Your browser doesn't support javascript.
loading
Left ventricular active strain energy density is a promising new measure of systolic function.
MacIver, David H; Agger, Peter; Rodrigues, Jonathan C L; Zhang, Henggui.
Affiliation
  • MacIver DH; Department of Cardiology, Taunton & Somerset Hospital, Musgrove Park, UK. david.maciver@manchester.ac.uk.
  • Agger P; Biological Physics Group, Department of Astronomy and Physics, University of Manchester, Manchester, UK. david.maciver@manchester.ac.uk.
  • Rodrigues JCL; Comparative Medicine Lab, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Zhang H; Department of Radiology, Royal United Hospital Bath NHS Trust, Bath, UK.
Sci Rep ; 12(1): 12717, 2022 07 26.
Article in En | MEDLINE | ID: mdl-35882913
The left ventricular ejection fraction does not accurately predict exercise capacity or symptom severity and has a limited role in predicting prognosis in heart failure. A better method of assessing ventricular performance is needed to aid understanding of the pathophysiological mechanisms and guide management in conditions such as heart failure. In this study, we propose two novel measures to quantify myocardial performance, the global longitudinal active strain energy (GLASE) and its density (GLASED) and compare them to existing measures in normal and diseased left ventricles. GLASED calculates the work done per unit volume of muscle (energy density) by combining information from myocardial strain and wall stress (contractile force per unit cross sectional area). Magnetic resonance images were obtained from 183 individuals forming four cohorts (normal, hypertension, dilated cardiomyopathy, and cardiac amyloidosis). GLASE and GLASED were compared with the standard ejection fraction, the corrected ejection fraction, myocardial strains, stroke work and myocardial forces. Myocardial shortening was decreased in all disease cohorts. Longitudinal stress was normal in hypertension, increased in dilated cardiomyopathy and severely decreased in amyloid heart disease. GLASE was increased in hypertension. GLASED was mildly reduced in hypertension (1.39 ± 0.65 kJ/m3), moderately reduced in dilated cardiomyopathy (0.86 ± 0.45 kJ/m3) and severely reduced in amyloid heart disease (0.42 ± 0.28 kJ/m3) compared to the control cohort (1.94 ± 0.49 kJ/m3). GLASED progressively decreased in the hypertension, dilated cardiomyopathy and cardiac amyloid cohorts indicating that mechanical work done and systolic performance is severely reduced in cardiac amyloid despite the relatively preserved ejection fraction. GLASED provides a new technique for assessing left ventricular myocardial health and contractile function.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiomyopathy, Dilated / Heart Failure / Amyloidosis / Hypertension Limits: Humans Language: En Journal: Sci Rep Year: 2022 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiomyopathy, Dilated / Heart Failure / Amyloidosis / Hypertension Limits: Humans Language: En Journal: Sci Rep Year: 2022 Document type: Article Country of publication: United kingdom